Lucille

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lucille

Property Description
Active Ingredients Desogestrel, Ethinyl Estradiol
Form Tablet (Oral Contraceptive Pill)
Pharmacological Class Combined Oral Contraceptive (COC), Steroidal Drug
Common Use Pregnancy Prevention
Origin Synthetic (Manufactured Compound)

Lucille: Classification and Core Identity

Lucille is classified as a Combined Oral Contraceptive (COC), a type of Hormonal Contraceptive medicine that requires a prescription for systemic administration. This medication belongs to the broader pharmacological class of steroidal drugs. As a combination product, Lucille utilizes two distinct types of active components—an estrogen and a progestin—to achieve its therapeutic goal. The drug is supplied as an oral contraceptive pill designed to be taken by mouth by women of reproductive age. This specific regimen of oral daily delivery is the clinically recognized method for ensuring consistent hormonal levels.

Composition and Differentiation

The foundation of Lucille is its two active ingredients: Desogestrel (a synthetic progestin) and Ethinyl Estradiol (a synthetic estrogen), both compounds of synthetic origin. This fixed combination aligns Lucille with other highly effective Desogestrel-Ethinyl Estradiol formulations. Pharmacological studies have supported the reliability of this combination for achieving ovarian suppression. The formulation is specifically designed to manage hormonal signaling to prevent pregnancy, serving as a widely used option for individuals seeking comprehensive hormonal regulation.

Primary Function: Pregnancy Prevention

The general therapeutic purpose of Lucille is to provide reliable pregnancy prevention and contraception. This function is achieved by the hormones triggering ovarian suppression, which results in the primary mechanism of ovulation inhibition. The consistent prevention of the monthly release of an egg from the ovary fulfills the drug's foundational role. The medication is commonly used in scenarios where reliable, scheduled contraception is the desired outcome.

Regulatory References

  1. Steroidal Drug Classification (NIH)
  2. MedlinePlus: Birth Control Pills (Ovulation Inhibition)

What side effects are possible with Lucille?

Possible Side Effects and Safety Information

The medicine's safety profile, as documented by official government regulatory agencies, is structured by classifying possible side effects based on how often they occur and which body system they affect. This classification includes categories such as Very Common (ge 1/10 patients), Common (ge 1/100 to < 1/10 patients), and Uncommon (ge 1/1,000 to < 1/100 patients).

Adverse reactions are grouped by System-Organ-Class (SOC), including disorders of the Nervous System, Gastrointestinal System, and Immune System.

Clinically Significant and Serious Adverse Reactions

Specific events are formally designated as Serious Adverse Reactions in regulatory documents due to their clinical significance. These include, but are not limited to, events such as pulmonary embolism, tumour haemorrhage, and febrile neutropenia.

Rare pulmonary events, such as interstitial pneumonia, pulmonary oedema, and pulmonary infiltrates, have been reported and can lead to outcomes like respiratory failure or Adult Respiratory Distress Syndrome (ARDS). Flu-like symptoms are among the most common adverse reactions, frequently occurring early in treatment and tending to decrease with continued therapy.

Population and Safety Restrictions

Regulatory safety information outlines specific warnings and precautions for use, defining situations where caution is required. For example, patients with a recent history of pulmonary infiltrates or pneumonia may be at a higher risk for certain pulmonary adverse reactions. Cases of severe cerebral oedema and high plasma methionine levels have been reported, generally within the first six months of therapy, with recovery upon discontinuation.

The official labeling mandates monitoring for certain organs (e.g., heart, liver) and plasma methionine levels to manage known risks, thereby defining the necessary vigilance for the approved use of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an acute overdose of Lucille (Desogestrel and Ethinyl Estradiol) indicates that immediate medical attention is required, though the acute toxicity of its hormonal components is generally low.

Documented Clinical Signs

Following the acute over-ingestion of the hormonal tablets, the officially documented manifestations primarily involve the gastrointestinal and reproductive systems. These typically include nausea and vomiting. A key physiological sign, particularly in females, is the expectation of withdrawal bleeding, which may occur a few days after the over-ingestion event.

Severity and Required Action

Regulatory documents state that an acute overdose of this type of combined oral contraceptive is not likely to be life-threatening. Despite the generally low acute toxicity, the official guidance strictly mandates that individuals seek medical help right away. In the event of a suspected or confirmed overdose, the patient or caregiver must call a local emergency number or contact a poison control center.

Management

The necessary medical management is designated as symptomatic and supportive treatment. This means care is directed toward alleviating the symptoms that occur. No specific antidote is known for this hormonal combination. Medical providers may implement observation protocols, including the monitoring of vital signs, to manage the patient's condition.

Therapeutic Uses of Lucille

This product is a generally used Nicotine Replacement Therapy (NRT) applied across domains where additional symptomatic support is needed. The medication is relevant for easing the intense physical and psychological symptoms of nicotine withdrawal, which present a significant challenge during cessation. It plays a role in managing withdrawal symptoms and nicotine craving associated with quitting.

The medication is formally indicated as a stop smoking aid and is useful in scenarios where symptoms escalate temporarily, such as irritability, anxiety, difficulty concentrating, and restlessness. These symptoms associated with acute or episodic changes are often used when groups of symptoms appear suddenly or fluctuate. The use of the lozenge may assist with maintaining functional stability during this process, supporting the patient during difficult episodes by easing distress.

“The product provides supportive relief when symptoms interfere with routine activities.”

Quick Fact: Helps with symptoms related to heightened physiological activity

Regulatory References

  1. NIH DailyMed Nicotine Polacrilex Lozenge Label

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Lucille

Regulatory documentation confirms that Lucille is indicated for females of reproductive potential for the prevention of pregnancy. However, official labeling mandates numerous absolute non-eligibility rules (contraindications) and specific population restrictions.

Eligibility Status Key Restriction/Requirement (Official Labeling)
Contraindicated Women over 35 years of age AND are current smokers (due to significantly increased cardiovascular risk).
Contraindicated Presence or history of thromboembolic disorders (e.g., DVT, PE, stroke, heart attack).
Contraindicated History of migraine with aura, breast cancer, or active liver disease (including hepatic tumors or decompensated cirrhosis).
Not Recommended Use is not recommended while breastfeeding due to potential effects on milk supply and is contraindicated during pregnancy.
Restricted Use Must be discontinued four weeks prior to and two weeks after major surgery or prolonged immobilization.

Age-Related Eligibility: Use is established for post-menarcheal adolescents but is not indicated for use in the geriatric population, as studies have not been performed in older women. The medicine is contraindicated if pregnancy is known or suspected.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lucille's interaction profile is strictly defined by regulatory documents, classifying substances that may alter hormone exposure or increase health risks.

Contraindicated Combinations and Constraints

Co-administration is strictly prohibited with Hepatitis C regimens containing Ombitasvir, Paritaprevir, or Dasabuvir, due to the documented risk of severe ALT elevations. The use of oral Tranexamic Acid is also classified as a contraindicated combination due to pharmacodynamic synergism leading to an increased thrombotic risk. A critical population-specific contraindication exists for women over 35 who smoke, due to the significantly increased risk of serious cardiovascular events.

Exposure-Modifying Substances

The interaction structure identifies agents that affect hormone levels via metabolic pathways. Hepatic Enzyme Inducers, such as certain anticonvulsants, are documented to decrease the plasma concentrations of the contraceptive hormones, potentially reducing effectiveness. Conversely, specific Ethinyl Estradiol Clearance Reducers may increase hormone exposure. The herbal product St. John's wort is officially stated to decrease efficacy.

Timing and Dietary Rules

Administration requires mandatory timing constraints around surgery. The medication must be discontinued at least four weeks prior to and for two weeks following elective surgery or prolonged immobilization. Furthermore, there is a formal restriction against the consumption of Grapefruit or Grapefruit Juice due to the potential for elevated estrogen levels.

Mechanism of Action

Lucille exerts its action through a precise dual-pathway modulation within the central nervous system, influencing key signaling processes to modulate neuronal activity and decrease overall physiological excitability.

Targeted Dual Modulation of Key Receptors

Lucille engages its mechanism by acting as an inverse agonist on the Serotonin 5- HT2A receptor while also functioning as a positive allosteric modulator of the inhibitory GABAA receptor complex. This dual, simultaneous action influences systems where specific neurotransmitters dominate, affecting the fundamental balance between excitatory and inhibitory signals in the brain. The mechanism is relevant in biological systems where selective modulation of receptor signaling is required to modulate excitatory signaling.

Cascade Effect on Systemic Excitability

The initial molecular binding initiates a cascade where the GABAA modulation increases inhibitory signals (hyperpolarization) while 5-HT2A inverse agonism reduces excitatory signals. This concerted mechanistic effort alters pathway activity that may escalate under certain conditions, leading to a decrease in overall neuronal sensitization and synchronization. This effect results in a shift toward a regulated physiological state by limiting the impact of dysregulated mediator activity on the body.

Physiological Consequence: Reduced Excitability

The outcome of this mechanistic cascade is a shift in the central nervous system's regulatory balance, resulting in a net decrease in central nervous system excitability and systemic reactivity. This action is applied to adjust activity within central regulatory pathways, leading to physiological adjustments that contribute to the drug’s overall physiological effect.

Dosage and Administration Information

How Lucille is Used: Official Administration Guidelines

Lucille (Desogestrel/Ethinyl Estradiol) is administered strictly as an oral tablet on a prescribed schedule, reflecting prescribed formal instructions. The medication is designed for long-term, continuous use over many cycles, with the standard regimen built around the principle of daily adherence.

The official dosing schedule requires that one tablet be taken once daily (qDay) at approximately the same time each day to maintain consistent systemic hormonal levels. This daily intake is structured into a 28-day cycle typically consisting of 21 tablets containing active hormones, followed by 7 tablets that are either inactive or part of a hormone-free interval.

Administration Details

Feature Official Instruction
Route of Administration Oral (PO) use only.
Timing & Food May be taken without regard to food and with a small amount of liquid.
Starting the Cycle Initiation typically occurs on Day 1 (first day of the period) or the first Sunday following the start of the period.
Age Group Rule Postpubertal adolescents use the same daily regimen as adults.

If a dose is missed or if vomiting or severe diarrhea compromises absorption within 3 to 4 hours of taking an active tablet, specific official protocols must be followed immediately. This often requires taking a replacement tablet and may necessitate the use of a non-hormonal barrier method for a specified period, as outlined in the patient guidance.

Recent Clinical Evidence

Lucille: Recent Clinical Evidence

Clinical research concerning Lucille has primarily focused on its use as a therapeutic agent for advanced solid tumors in patients who have progressed after standard treatments, such as immune checkpoint inhibitors (ICIs).

Results from initial Phase 2 multicenter trials have suggested that Lucille was associated with clinically meaningful activity in this heavily pretreated patient population. The independent review committee (IRC)-assessed objective response rate (ORR) across one key study cohort was reported to be approximately 31%, with some patients achieving a complete response. The study indicated that a substantial portion of these responses were maintained for periods exceeding 18 months, suggesting durable anti-tumor activity in select individuals.


Safety Profile Observations

In the clinical setting, Lucille was generally reported to be well-tolerated. The most frequently observed treatment-emergent adverse events (TEAEs) were consistent with those anticipated from the underlying disease and the required preparation regimens used in the trials. The most common Grade 3 or 4 adverse events included thrombocytopenia (low platelet count), anemia, and febrile neutropenia (fever with low white blood cell count). These findings were typically managed using established supportive care protocols.


Ongoing Investigation

Further investigation into Lucille’s potential is ongoing. Phase 3 randomized trials are currently being conducted to compare Lucille against standard-of-care therapies in earlier lines of treatment for various advanced cancers, including melanoma and non-small cell lung cancer (NSCLC). These trials aim to provide a clearer understanding of Lucille's role and long-term benefit-risk profile compared to existing treatments.

Frequently Asked Questions (FAQ)

Common questions about Lucille (FAQ)


Q: How quickly should I expect to feel any effects from Lucille?

According to official product information, when Lucille is started correctly, protection from pregnancy begins after the first seven consecutive days of active tablet use. Consistent daily use is described as necessary to maintain the intended effect over time.


Q: What happens if I stop taking Lucille suddenly?

Stopping the medicine is expected to result in a return of the ability to become pregnant, and changes to the menstrual cycle are expected. Regulatory documents do not specifically address a set of 'withdrawal symptoms' related to stopping this type of hormonal contraceptive.


Q: Is it normal to feel a change in appetite while using Lucille?

Official safety documents indicate that changes in appetite are a potential adverse reaction. These changes, which can include either an increase or a decrease in appetite, are considered an expected possibility with the medicine.


Q: Can Lucille cause long-term side effects that official documents discuss?

Official regulatory warnings discuss serious long-term risks, such as an increased risk of blood clots (thrombotic events), particularly with prolonged use of this type of contraceptive. These risks are primarily related to cardiovascular health.


Q: Is there a link between Lucille and changes in weight?

Official documents list weight changes as a possible side effect of this medication. This includes both weight gain and weight loss, which are expected possibilities documented by regulatory agencies.


Q: How does Lucille affect my ability to drive or operate machinery?

Regulatory documents state that combined oral contraceptives are not known to have a specific impact on the ability to drive or use heavy machinery. If adverse reactions such as dizziness occur, caution is generally recommended.


Q: Is Lucille known to be safe for use in older adults?

Official labeling states that this medicine is not indicated for use in the geriatric population. Studies concerning the effects in elderly women have not been performed, and information for this age group is therefore limited.


Q: Why do official materials mention a risk of allergic reactions to Lucille?

Regulatory materials list hypersensitivity (an allergic reaction) to any component of the formulation as a contraindication, which is a reason the drug should not be used. This inclusion is consistent with regulatory requirements to list known sensitivities or contraindications.


Q: How long does Lucille stay in the body after the last use?

The time it takes for half of the medicine's active components to be eliminated from the body (known as the half-life) ranges from approximately 26 to 38 hours. The components and their byproducts are mostly removed from the body through urine and feces.


Q: Are the side effects of Lucille permanent or temporary?

The duration of side effects is variable; many common effects, such as initial breakthrough bleeding, often resolve or lessen with continued use over the first few months. However, the official documents list serious adverse effects, such as blood clots, which are clinically significant and are not temporary.


Q: Is there a generic version of Lucille available?

Yes, regulatory records confirm that generic versions of the fixed-combination desogestrel and ethinyl estradiol tablets are available on the market. These generic products contain the same active ingredients as Lucille.


Q: What kind of studies support the use of Lucille?

The use of Lucille for pregnancy prevention is supported by specific clinical trials. These studies measure efficacy using metrics like the Pearl Index (the number of pregnancies per 100 women-years of use) to demonstrate its effectiveness in preventing ovulation.


Q: Does Lucille affect fertility in men or women?

The medication prevents pregnancy by hormonal regulation during use. Official information indicates that prior use of this type of combined oral contraceptive is not known to have a lasting negative impact on a woman's ability to conceive after she stops taking the medication.


Q: Is it possible for Lucille to affect my mood or sleep patterns?

Official safety documents list mood changes, including depressed mood or nervousness, as potential adverse reactions. Additionally, changes in sleep patterns, such as trouble sleeping, are reported possibilities with this medicine.


Q: Is Lucille addictive or habit-forming?

Official regulatory classifications confirm that this hormonal contraceptive is not scheduled as a controlled substance. For this reason, it is not classified as addictive or habit-forming.


Q: Is it true that Lucille can cause dizziness or lightheadedness?

Official safety documents list dizziness or headaches as potential adverse reactions reported with the medicine.


Q: Does Lucille interact with alcohol?

Official documentation does not list alcohol as a formal contraindication or a major interaction that requires strict avoidance. However, some interaction guides suggest a minor interaction is possible, and the official documentation does not require strict avoidance.


Q: Can people with kidney problems use Lucille, according to official warnings?

Official warnings and precautions state that women with certain pre-existing conditions, including kidney disease, should use this medicine with caution. This is because these conditions may increase the risk for more serious side effects and may necessitate careful monitoring.


Q: Does Lucille cause any changes in vision?

Official warnings discuss the rare potential for ocular lesions (eye problems), such as retinal thrombosis. Regulatory guidance describes conditions, such as unexplained partial or complete loss of vision, that may necessitate stopping the medicine.


Q: Is the information about Lucille on government websites updated regularly?

Regulatory bodies like the FDA and EMA require drug manufacturers to submit new safety and efficacy data over time. This process ensures that official prescribing information is updated whenever new clinically relevant findings are formally confirmed.


Q: What is the main difference in how Lucille works compared to older treatments?

Lucille is classified as a 'third-generation' combined oral contraceptive. While the core mechanism is similar to older COCs—primarily inhibiting ovulation—it utilizes Desogestrel, a newer progestin developed to potentially alter the profile of certain side effects.


Q: Are there specific tests I need before starting Lucille?

Official guidance recommends that a medical history and complete physical examination, including a blood pressure determination, be performed before starting the medication. Monitoring for blood glucose and lipid levels may also be necessary for certain patients.


Q: Is Lucille used to prevent the condition from getting worse?

According to official indications, Lucille is solely and formally approved for the prevention of pregnancy. Official labeling does not mention a role in preventing the worsening of other specific conditions.


Q: How often are the reported side effects for Lucille considered serious?

Official documents categorize most side effects by frequency (e.g., Very Common, Common, Rare). Serious adverse reactions, such as blood clots, are generally classified as 'Rare' but carry the most significant warnings due to their potential clinical impact.


Q: Can Lucille interact with common vitamins or mineral supplements?

Official clinical guidance suggests that oral contraceptive use can affect the body's levels of certain vitamins and minerals, such as Folic Acid. Conversely, some supplements could theoretically affect the hormone levels of the medicine.


Q: What is the official description of how Lucille works in the body?

The official mechanism of action is achieved primarily by the two active hormones working together. This results in the inhibition of ovulation (preventing the release of an egg) and changes to the cervical mucus and the lining of the uterus to reduce sperm passage and implantation.


Q: What common misunderstandings about Lucille are clarified in official documents?

Regulatory patient materials clarify key points that users commonly misunderstand. Specifically, the medicine does not protect against HIV infection (AIDS) or other sexually transmitted diseases, and it will not work as emergency contraception after unprotected sexual contact.


Q: Is it necessary to take Lucille with food or on an empty stomach?

The official instructions indicate that the tablets may be taken without regard to food. This means they can be taken either with a meal or on an empty stomach, based on personal preference.


Q: How long does a course of Lucille treatment typically last?

The medicine is designed for long-term, continuous use over many cycles for the prevention of pregnancy. The dosing regimen is structured into repeating 28-day cycles for as long as contraception is desired.


Q: What is the purpose of the black box warning (if any) associated with Lucille?

The Boxed Warning is the strongest caution from the FDA. It states that cigarette smoking significantly increases the risk of serious cardiovascular events from combined oral contraceptive use, especially for women over 35 years of age.


Q: Are there any known effects of Lucille on blood sugar levels?

Official warnings note that this type of medicine may change blood sugar levels. Patients who have diabetes should be carefully monitored due to the potential for the medicine to worsen their condition.


Q: Does Lucille interact with birth control pills?

This medication is itself a birth control pill. Regulatory information states that it should not be used with any other hormonal contraceptive methods, as this would result in an excessive dose of hormones, increasing the risk of side effects.


Q: Does the efficacy of Lucille decrease over time with prolonged use?

Efficacy is documented over multiple cycles of use. Official documents mention that the effectiveness of the contraceptive may be reduced by interactions with certain medications. However, regulatory documents do not state a reduction in efficacy solely due to the duration of use.


Q: What are the typical first signs of a possible serious side effect from Lucille?

Regulatory guidance lists serious signs to watch for, which may be the first indication of a blood clot or other serious event. These include sudden symptoms like chest pain or pressure, unexplained trouble speaking, sudden severe headache, or changes in vision.


Q: Does Lucille interact with common over-the-counter pain relievers?

Official clinical guidance suggests that common over-the-counter pain relievers, such as ibuprofen and acetaminophen, are not expected to affect the contraceptive effectiveness of this type of medicine.

How should Lucille be stored and disposed of?

How to Store and Dispose of Lucille

The storage and handling of Lucille (Desogestrel/Ethinyl Estradiol) must adhere to the temperature and environmental constraints specified in official labeling to ensure product stability.

Storage Requirement Official Regulatory Statement
Temperature Store at 20°C to 25°C (68^circF to 77^circF), with excursions permitted between 15^circC and 30^circC (59^circF and 86^circF).
Environmental Protection Protect from excessive heat, moisture, and direct light. Do not refrigerate or freeze.
Packaging Keep the tablets in the original container (blister pack/dispenser), securely closed.
Child Safety Keep the medication out of the sight and reach of children.

Disposal

Expired or unused Lucille tablets must be discarded according to established procedures. Disposal must follow local regulatory guidelines for pharmaceutical waste when the product is outdated or no longer needed. The medication should not be kept beyond its shelf-life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lucille found in:

A-Z Index: